Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record.

CHOLINERGIC APPROACHES TO THE TREATMENT OF ALZHEIMER'S DISEASE

Hollander, Eric, Mohs, Richard C, Davis, Kenneth L·1986·British Medical Bulletin

Abstract

Aizheimer's disease (AD) is a major mental health problem involving abnormalities of several neurotransmitter systems in the brain. The most consistent and pervasive abnormality involves the cholmergic system, and correlates with severity of illness in AD. Pharmacological enhancement of cholinergic activity includes presynaptic agents which increase acetylcholine (ACh) synthesis and release; synaptic agents which increase ACh by limiting its breakdown; and postsynaptic agents which directly stimulate ACh receptors. Valid trials of cholinergic agents in AD require a specialized study design in which individualized optimal drug doses are tested in a large population of stringently diagnosed AD patients. Testing devices must be suitable for each patient's capabilities, and should measure alterations of function in several areas. Clinical trials with choline and lecithin, ACh precursors, have not shown cognitive improvements in AD patients. Combination of precursors with agents that enhance the firing rate of presynaptic neurons, such as piracetam, may have some beneficial effect in a subgroup of AD patients with remaining functionally intact cholinergic neurons. Red cell-plasma choline ratio appears to be higher in treatment responders. Presynaptic approaches have the advantage of mimicking the phasic action of cholinergic cells, but require the presence of functionally intact cholinergic neurons. Physostigmine, an acetycholinesterase (AChE) inhibitor, augments available synaptic ACh. Studies with intravenous physostigmine show significant but moderate transient improvement in memory test, but applicability is limited by short half-life. Oral, like intravenous, physostigmine has a narrow therapeutic window, necessitating the use of a dose-finding phase in study design. Oral physostigmine has yielded modest improvements in specific cognitive areas and overall functioning in a majority of AD patients. Biochemical measures of central cholinergic activity such as plasma cortisol and cerebrospinal fluid AChE activity have been correlated with symptom improvement, and may identify likely responders. Cholinergic agonists such as Rs 86, erecoline and oxotremorine have been used in preliminary trials with AD patients, yielding modest results with significant side effects. Future directions include the development of more specific, long-acting cholinergic agents with fewer side effects; differentiating M-1 and M-2 receptor sites; delineation of parameters that can predict response, and possibly the use of combined neurotransmitter enhancement treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/oxfordjournals.bmb.a072106

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 158

Metadata

Authors
Hollander, E., Mohs, R. C., & Davis, K. L.
Venue
British Medical Bulletin
Published
1986
Volume
42
Issue
1
Pages
97-100
ISSN
  • 0007-1420 (ISSN-L)
  • 1471-8391
OpenAlex
W2344563485
Cited by
158
References
0
FWCI
15.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CHOLINERGIC APPROACHES TO THE TREATMENT OF ALZHEIMER'S DISEASE. https://app.cochat.ai/papers/10.1093/oxfordjournals.bmb.a072106
The paper
Hollander, E., Mohs, R. C., & Davis, K. L. (1986). CHOLINERGIC APPROACHES TO THE TREATMENT OF ALZHEIMER'S DISEASE. British Medical Bulletin. https://doi.org/10.1093/oxfordjournals.bmb.a072106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.